1. Home
  2. INBK vs ALXO Comparison

INBK vs ALXO Comparison

Compare INBK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Internet Bancorp

INBK

First Internet Bancorp

N/A

Current Price

$27.11

Market Cap

255.0M

Sector

Finance

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.32

Market Cap

205.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INBK
ALXO
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
255.0M
205.9M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
INBK
ALXO
Price
$27.11
$1.32
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
★ $30.90
$4.60
AVG Volume (30 Days)
37.0K
★ 930.4K
Earning Date
10-21-2026
11-06-2026
Dividend Yield
★ 0.91%
N/A
EPS Growth
N/A
★ 26.36
EPS
★ 0.55
N/A
Revenue
★ $11,541,000.00
N/A
Revenue This Year
$18.94
N/A
Revenue Next Year
$14.34
N/A
P/E Ratio
$47.40
★ N/A
Revenue Growth
★ 101.84
N/A
52 Week Low
$17.05
$1.05
52 Week High
$31.09
$2.66

Technical Indicators

Market Signals
Indicator
INBK
ALXO
Relative Strength Index (RSI) 39.74 29.67
Support Level $25.04 $1.37
Resistance Level $30.04 $1.56
Average True Range (ATR) 0.89 0.10
MACD -0.16 -0.03
Stochastic Oscillator 40.87 12.32

Price Performance

Historical Comparison
INBK
ALXO

About INBK First Internet Bancorp

First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: